Stock Analysis
Arrowhead Research CorporationARWR
Sector: Healthcare · Industry: Pharmaceutical Preparations
AnalystsStrong Buy20 analystsPrice is 36% of the way from the year's low to its high.
Cash covers 116% of debt · Q3 2026.
PMP Verdict
Weak fundamentals
Strengths
- Financial Health68
Risks
- Profitability0
- Quality15
Weak fundamentals — valuation is the only support.
Market context
-4.4% today· Z 1.4σ
Bull Case
- ✓Revenue CAGR 56.5% — durable top-line growth
What's happening with ARWR
Profile
profitability, moat, earnings quality, valuation and growth lag behind.
How is each axis scored?
- Valuation25/100 · Weak
- P/E vs own history (n/a)10/25
- FCF yield (-0.9%)0/25
- P/S (11.8x)5/25
- EV/EBIT (n/a)10/25
- Growth25/100 · Weak
- Revenue CAGR (56.5%)25/25
- Net income CAGR (n/a)0/25
- EPS CAGR 5Y (n/a)0/25
- Fwd implied growth (n/a)0/25
- Profitability0/100 · Weak
- ROIC (-72.3%)0/25
- ROE (-68.7%)0/25
- Net margin (-47.8%)0/25
- Operating margin (-33.8%)0/25
- Financial Health68/100 · Moderate
- Altman Z (2.17)18/25
- Current ratio (5.90)25/25
- Interest coverage (-20.8x)0/25
- Net cash / debt (Net cash)25/25
- Quality15/100 · Weak
- Piotroski F (5/9)15/25
- Beneish M (4.27)0/25
- FCF conversion (n/a)0/25
- Margin stability (σ 13813.9%)0/25
- Moat0/100 · Weak
- ROIC >12% years (1/8 yrs)0/25
- Median gross margin (n/a)0/25
- FCF-positive years (3/9 yrs)0/25
- Worst-year net margin (worst -16882.4%)0/25
Risk Flags
- ⚠Beneish M 4.27 — earnings-manipulation flag
- ⚠Negative FCF margin (-0.1%) — burning cash
- ⚠SBC 10.5% of revenue — real dilution cost
- ⚠9 loss-making years in recent history
- ⚠Interest coverage -20.8× — thin debt cushion
About Arrowhead Research Corporation
Arrowhead Pharmaceuticals Inc is a commercial-stage pharmaceutical company. Show more
It is focused on the development of medicines for diseases associated with genetic abnormalities or protein overproduction. The company develops potential RNAi therapies designed to inhibit the expression of genes known to trigger diseases. Its portfolio includes potential drugs targeting Cardiometabolic, Neuromuscular, Pulmonary, Liver, and other diseases. The company also develops RNAi products and clinical candidates designed to target different cell types within the body.
Headquarters: PASADENA, CA · Employees: 711 · Website ↗
Price History
Weekly Candlestick Chart — up to 5Y
Key Metrics
Financial snapshot · Tap any metric for its definition and grade
TTM Snapshot
trailing twelve months · YoYValuation
25EP/E (TTM)—
Price / TTM EPS (own statements)
P/FCF77.9xD
Grade D: ExpensivePrice / Free Cash Flow per share (Finnhub). Inverse of FCF yield — negative when FCF is negative
FCF Yield-0.9%D
Grade D: NegativeTTM (OCF − CapEx) / Market Cap — vs own 5Y history: -33.2%–4.2% · 59th pct
P/S (TTM)11.83xD
Grade D: ExpensivePrice / TTM Revenue (own statements) — vs own 5Y history: 2.4x–1075.2x · 26th pct
EV/EBITDA29.1xD
Grade D: ExpensiveEnterprise value / EBITDA (Finnhub) — capital-structure neutral
EV/Sales14.2xD
Grade D: Very expensiveEnterprise Value / TTM Revenue (Finnhub) — capital-structure neutral sales multiple
Forward P/E—
Price / next-year EPS estimate — shows whether the TTM multiple is rich or just front-loading growth
P/B Ratio16.99xD
Grade D: Very expensivePrice to Book Value. Neg. equity = heavy buybacks
PEG Ratio-0.34A
Grade A: CheapFinnhub PEG — their P/E basis ÷ expected EPS growth. Suppressed when their P/E diverges >2× from our TTM P/E (different basis)
Dividend Yield—
TTM dividend yield (Finnhub) — annual dividends / price. None = no dividend; very high yield can signal distress
Payout Ratio—
Dividends / Net Income (Finnhub) — share of earnings paid out; >90% or negative = unsustainable
Profitability
0EROIC-72.3%D
Grade D: LowNOPAT (EBIT less ~21% tax) / invested capital (equity + debt − cash). Flagship quality metric — durable >15% signals a moat
ROE-68.7%D
Grade D: WeakReturn on Equity. Neg. equity = heavy buybacks
ROA-17.4%D
Grade D: WeakReturn on Assets (Finnhub) — Net Income / Total Assets; how efficiently assets produce profit
Net Margin-47.8%D
Grade D: LowNet Income / Revenue
Operating Margin-33.8%D
Grade D: LowTTM EBIT / TTM Revenue
Gross Margin100.0%A
Grade A: PremiumGross Profit / Revenue
FCF Margin-11.2%D
Grade D: LowFCF / Revenue
True FCF Margin-21.7%D
Grade D: LowTTM (OCF − CapEx − SBC) / TTM Revenue — SBC treated as a real cost
Growth
25ERevenue CAGR56.5%A
Grade A: HighCompound annual revenue growth (up to 5Y depending on data availability)
Net Income CAGR—
Compound annual net income growth (up to 5Y depending on data availability)
EPS CAGR (5Y)—
Compound annual EPS growth over up to 5Y of per-share earnings (own statements). Null when either endpoint EPS ≤ 0
Implied EPS Growth—
Analyst forward EPS (normalized basis) vs our GAAP TTM EPS — different bases, so extreme values usually mark cyclically depressed TTM earnings, not real growth
Dilution (5Y)+36.4%D
Grade D: DilutiveShare count change over 5Y
SBC / Net Income—
Stock-based comp/Net income. >30% = dilution risk
SBC / Revenue10.5%D
Grade D: HighTTM stock-based comp / TTM Revenue
Financial Health
68BAltman Z-Score2.17C
Grade C: Gray zoneBankruptcy risk. >3 Safe, <1.8 Distress
Current Ratio5.90xA
Grade A: HighCurrent Assets/Liabilities
Quick Ratio5.81xA
Grade A: High(Current Assets − Inventory) / Current Liabilities (Finnhub) — stricter liquidity test, excludes inventory
Interest Coverage-20.8xD
Grade D: RiskyEBIT/Interest. >10 Strong
Debt RepaymentNet CashA
Grade A: FastYears to repay net debt via FCF
Net Debt/EBIT1.0xA
Grade A: LowLeverage. <2x Low, >4x High
Debt/Equity2.96xD
Grade D: HighDebt / Equity: <1 Conservative, >2 Risky. Not meaningful with non-positive equity; shown as unavailable rather than low debt.
Cash / Debt1.16xA
Grade A: CoveredCash covers how much of total debt. >1 = could repay all debt from cash
Quality
15EPiotroski F-Score5/9C
Grade C: AverageFinancial strength 0–9. >7 Strong
Beneish M-Score4.27D
Grade D: RiskyEarnings manipulation risk. < -2.22 Safe
FCF Conversion—
FCF / Net Income
Margin Stability13813.9%D
Grade D: VolatileEBIT margin std deviation. Lower = stable
Capex / Revenue2.4%A
Grade A: Asset-lightTTM CapEx / TTM Revenue — high % = capital-hungry business
Asset Turnover0.36xD
Grade D: LowRevenue / Total Assets (Finnhub) — how efficiently the asset base generates sales
Insider Transactions
SEC Form 4 · 8 recordsP/S codes are the directional signal; grants, option exercises and tax withholding carry none. Form 4 doesn't flag 10b5-1 plans — scheduled sales may appear within open-market sells.
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
PERRY MICHAEL S Filed | PERRY MICHAEL S | SellOpen market sale | -11600 | |
OLUKOTUN ADEOYE Y Filed | OLUKOTUN ADEOYE Y | SellOpen market sale | -2000 | |
Lu Hongbo Filed | Lu Hongbo | SellOpen market sale | -2970 | |
Hamilton James C Filed | Hamilton James C | SellOpen market sale | -10000 | |
Apel Daniel Joseph Filed | Apel Daniel Joseph | SellOpen market sale | -8730 |
Show 3 more filingsShow fewer filings
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
Apel Daniel Joseph Filed | Apel Daniel Joseph | SellOpen market sale | -1157 | |
Apel Daniel Joseph Filed | Apel Daniel Joseph | SellOpen market sale | -3208 | |
Hamilton James C Filed | Hamilton James C | SellOpen market sale | -10000 |
More metrics — Moat, Per Share, Balance Sheet, MarketHide additional metrics
Moat
0EROIC >12% Years1/8 yrsD
Grade D: WeakShare of completed fiscal years with ROIC > 12% — measures multi-year capital-return durability
Gross Margin (Med.)—
Median annual gross margin across available fiscal years — pricing-power durability
FCF-Positive Years3/9 yrsD
Grade D: WeakShare of completed fiscal years with positive free cash flow
Net Margin Floor-16882.4%D
Grade D: WeakWeakest annual net margin across completed fiscal years — recession/downcycle resilience
Per Share
EPS (TTM)—
TTM net income per share (Finnhub fallback)
Cash / Share$11.32
Cash & short-term investments per share (Finnhub)
Book Value / Share$3.30
Shareholders' equity per share (Finnhub). Negative = accumulated losses / heavy buybacks
Balance Sheet
Total Debt$1.38B
Total debt obligations (short + long term)
Cash & Equiv.$1.60B
Cash and short-term investments
Net Debt$-218.46MA
Grade A: Net CashTotal Debt minus Cash. Negative = Net Cash position
Total Equity$466.04M
Shareholders' equity (book value)
Asset / Liability1.28xC
Grade C: AdequateTotal Assets / Total Liabilities
Market
Market Cap$7.92B
Current Market Capitalization
Beta1.34C
Grade C: VolatilePrice sensitivity vs the market (Finnhub) — 1.0 moves with market, >1.2 amplifies swings
How grades work: each metric is graded A–D against fixed thresholds (tap a row for the meaning). Card grades map the pillar score to A+–E — a card grade is that pillar's own score, not an average of the rows shown.
Financials as of Jun 2026 · Ratio snapshot Oct 17, 2026
Key Insights: Arrowhead Research Corporation (ARWR)
ARWR is down 4.44% at the last close. Piotroski F-Score of 5/9 indicates mixed fundamentals for Arrowhead Research Corporation. Altman Z-Score of 2.17 falls in the grey zone (1.81–2.99) — financial distress is unlikely but not ruled out. Beneish M-Score of 4.27 is above the −1.78 flag threshold, a signal that reported earnings warrant closer scrutiny. Revenue has compounded at roughly 56% annually — a strong growth profile.
- Free-cash-flow margin is negative (-11%) — the business currently burns cash.
- Company is effectively debt-free after netting cash.
- Interest coverage of -20.8× leaves little room for earnings shocks.
- Arrowhead Research Corporation posted a net loss in 8 of 9 available completed fiscal years (2017–2025).
- At a valuation score of 25/100, ARWR trades at a premium to its historical multiples.
See how ARWR ranks on the Capex Tracker — top 50 capital spenders compared.
Recent Market Moves
See all ARWR moves →| Date | Session | Price | Move | Z-Score |
|---|---|---|---|---|
| Sep 21 | Regular | 68.79 | +3.47% | 2.32 |
| Sep 21 | After-hours | 68.58 | +3.16% | 2.11 |
Frequently Asked Questions about ARWR
What is the current Arrowhead Research Corporation (ARWR) stock price?
ARWR is trading at $55.90 at the last market close, down 4.44% on the session. PreMarketPrice tracks ARWR pre-market, intraday and after-hours prices.
Is ARWR stock a buy right now?
PreMarketPrice's quantitative model rates Arrowhead Research Corporation's financial health at 68/100. This is a data-driven snapshot of fundamentals, not investment advice.
Is ARWR stock overvalued?
Arrowhead Research Corporation trades at a trailing P/E of n/a and our valuation score rates it 25/100 (higher = cheaper vs. its own history). See the Valuation History and Key Metrics sections for forward P/E, EV/EBITDA and PEG context.
When does Arrowhead Research Corporation report earnings?
No confirmed earnings date is currently scheduled for ARWR. The Earnings section lists recent reports and updates as dates are announced.
What sector does Arrowhead Research Corporation operate in?
Arrowhead Research Corporation operates in the Healthcare sector, within the Pharmaceutical Preparations industry. The Related Stocks section lists sector peers for comparison.
What does Arrowhead Research Corporation do?
Arrowhead Pharmaceuticals Inc is a commercial-stage pharmaceutical company.
About Arrowhead Research Corporation (ARWR) Stock
Arrowhead Research Corporation (ARWR) is a US-listed stock operating in the Healthcare sector, specifically the Pharmaceutical Preparations industry. As of the latest update, Arrowhead Research Corporation is trading at $55.90, down 4.44% on the day with a market capitalization of $7.9 billion. The financial health score for ARWR is 68/100, which indicates good financial strength based on profitability, leverage, liquidity, and growth metrics. This page provides real-time pre-market pricing, earnings calendar, financial health analysis, and valuation metrics for ARWR stock.
ARWR Stock Analysis & Key Metrics
On PreMarketPrice, you can track Arrowhead Research Corporation (ARWR) across multiple dimensions:
- Pre-market price & movement: Real-time ARWR stock price with percentage change, updated continuously during pre-market and regular trading hours.
- Valuation & P/E history: Historical P/E, P/S, and P/B ratios for ARWR with trend analysis and normalized valuation multiples.
- Financial statements: Revenue, net income, assets, liabilities, and equity for Arrowhead Research Corporation across multiple reporting periods.
- Financial health score: A composite score of 68/100 based on Altman Z-Score, Piotroski F-Score, profitability, and leverage metrics for ARWR.
- Sector peers: Compare ARWR against 6 other healthcare stocks on key financial metrics.
Is ARWR a Good Stock to Buy?
This page provides data-driven analysis to help you evaluate Arrowhead Research Corporation (ARWR) as an investment. The financial health score of 68/100 suggests good financial fundamentals. Valuation metrics show whether the stock is trading above or below its historical average.However, this is not financial advice — always do your own research before investing.
Data on this page is sourced from real-time market feeds, Polygon.io, and Finnhub.Arrowhead Research Corporation (ARWR) trades on NYSE/NASDAQ. Pre-market trading occurs 4:00 AM – 9:30 AM ET. Regular market hours are 9:30 AM – 4:00 PM ET.